Development of a novel agent for lung cancer prevention
开发一种新型肺癌预防剂
基本信息
- 批准号:8401402
- 负责人:
- 金额:$ 7.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-09 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:A/J MouseAdverse effectsAffectAnimal ModelAspirinBioavailableBiological AssayBiological ModelsButanonesCancer EtiologyCancer ModelCarcinogensCessation of lifeChemopreventionChemopreventive AgentCleaved cellClinicalClinical ResearchClinical TrialsDNA AdductsDataDevelopmentDietDiseaseDoseEffectivenessEvaluationExcretory functionExhibitsFutureGoalsHumanHybridsHydrogen CyanideIbuprofenIncidenceIndividualIntakeInvestigationLeadLinkLiteratureLiver MicrosomesLungLung NeoplasmsMAP Kinase GeneMalignant NeoplasmsMalignant neoplasm of lungMaximum Tolerated DoseMediatingMetabolicMetabolismMinorModificationNational Cancer InstituteNon-Steroidal Anti-Inflammatory AgentsPI3K/AKTPTGS2 genePharmaceutical PreparationsPreventionPrevention strategyPreventiveProdrugsPropertyResearchSalineSideSignal PathwaySignal TransductionSmokerSmoking PreventionStructureStructure of parenchyma of lungTestingTherapeutic UsesTimeTobacco useTobacco-Associated CarcinogenToxic effectUnited StatesValidationWorkabsorptionanalogbasecancer typecarbenecarcinogenesisdesigndrug metabolismefficacy testingenzyme activityhigh riskin vivoindexinginnovationlung cancer preventionmortalitynovelpre-clinicalpreclinical studypreventselenocyanateselenolsmoking cessationtumortumorigenesisyeast two hybrid system
项目摘要
DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer related deaths in the United States. Despite the identification of several preventive agents and strategies, optimal prevention of lung cancer has not been achieved. More effective agents are therefore required that would safely achieve prevention without drastic side effects.Novel compounds which are rational modifications of well-established chemopreventive agents and follow a similar mechanism of action, but with enhanced potency, reduced toxicity, and lower dose requirement, may be clinically more relevant. Recently, we developed highly innovative hybrid molecules, p-XS-Asp and p-XS-Ibu, designed by conjugating two well known chemopreventive agents i.e. 1,4-phenylenebis(methylene)seleno- cyanate (p-XSC) and nonsteroidal anti-inflammatory drugs (NSAIDs) aspirin and ibuprofen, respectively, as potential agents for lung cancer prevention. The advantage of these agents is two-fold: (i) the combined p- XSC-NSAID hybrid drugs would generate the active p-XSeH putative metabolite similar to p-XSC but without the toxicity related to hydrogen cyanide (HCN); HCN is released as a side product on p-XSC metabolism but would not form in p-XS-NSAID metabolism, and (ii) the novel agents would function through releasing the corresponding NSAID, thus enhancing the overall chemopreventive efficacy of the hybrid molecule. Our preliminary studies supported this assumption and identified p-XS-Asp as the most potent and orally bioavailable agent. The overall goal of this project is to validate the potential of p-XS-Asp as a lung cancer chemopreventive agent. We hypothesize that p-XS-Asp would cleave in vivo to release the active p-XSeH, not releasing undesired HCN but aspirin, thus making it less toxic and more potent than p-XSC or aspirin alone. The objective of this proposal is to test the efficacy of p-XS-Asp for inhibiting lung tumor development using the A/J mouse lung cancer model and to begin evaluating the mechanism by which this agent exhibits its activity. The specific aims are: 1) evaluate the chemopreventive efficacy of p-XS-Asp in NNK-induced lung cancer, and 2) evaluate the mechanism of action(s) associated with chemopreventive effects of p-XS-Asp in NNK-induced tumorigenesis. We will use the experimental approach of determining the maximum tolerated dose (MTD) of dietary p-XS-Asp and evaluating its effectiveness for inhibiting tumor development in A/J mice injected intraperitonealy with one dose of 10 ¿mol NNK in saline. Furthermore, to begin establishing the mechanism, we will carry out its metabolism using liver microsomes to establish if p-XS-Asp will cleave into active metabolites p-XSeH and aspirin, and evaluate COX-2-mediated pro-mitogenic MAPK and pro-survival PI3K/AKT signaling pathways, which are known to be influenced by p-XSC and/or aspirin. These studies will begin establishing the potential of p-XS-Asp as lung cancer preventive agent. Long term, validation of p-XS- Asp as an effective and safe agent would reduce the chances of developing lung cancer, particularly, in smokers/former smokers thereby directly decreasing the mortality incidence.
PUBLIC HEALTH RELEVANCE: To date, there are no effective agents available for the prevention of lung cancer which, in ~90% of the cases, is attributed to tobacco use. The studies proposed here, will initiate validation of our recently developed hybrid agent p-XS-Asp as a potent and safe chemopreventive against NNK induced carcinogenesis and begin elucidating underlying mechanism of chemoprevention. If effective,this study would reveal a promising agent which, in near future, could prove capable of preventing lung cancer development in smokers.
描述(由申请人提供):肺癌是美国癌症相关死亡的主要原因。尽管确定了几种预防药物和策略,但尚未实现肺癌的最佳预防。因此,需要更有效的药物,将安全地实现预防而没有剧烈的副作用。新的化合物,是合理的修改完善的化学预防剂,并遵循类似的作用机制,但具有增强的效力,降低毒性,和较低的剂量要求,可能是临床上更相关。最近,我们开发了高度创新的杂化分子,p-XS-Asp和p-XS-Ibu,其通过将两种众所周知的化学预防剂即1,4-亚苯基双(亚甲基)硒氰酸酯(p-XSC)分别与非甾体抗炎药(NSAID)阿司匹林和布洛芬缀合而设计,作为潜在的肺癌预防剂。这些药剂的优点是双重的:(i)组合的p-XSC-NSAID杂合药物将产生类似于p-XSC的活性p-XSeH推定代谢物,但没有与氰化氢(HCN)相关的毒性; HCN作为p-XSC代谢的副产物释放,但不会在p-XS-NSAID代谢中形成,和(ii)新药剂将通过释放相应的NSAID发挥作用,从而增强杂合分子的总体化学预防功效。我们的初步研究支持了这一假设,并确定p-XS-Asp为最有效和口服生物利用度最高的药物。该项目的总体目标是验证p-XS-Asp作为肺癌化学预防剂的潜力。我们假设p-XS-Asp将在体内裂解以释放活性p-XSeH,不释放不需要的HCN,而是释放阿司匹林,从而使其毒性更小并且比单独的p-XSC或阿司匹林更有效。本提案的目的是使用A/J小鼠肺癌模型测试p-XS-Asp抑制肺肿瘤发展的功效,并开始评价该药剂显示其活性的机制。具体目标是:1)评价p-XS-Asp在NNK诱导的肺癌中的化学预防功效,和2)评价与p-XS-Asp在NNK诱导的肿瘤发生中的化学预防作用相关的作用机制。我们将使用实验方法确定膳食p-XS-Asp的最大耐受剂量(MTD),并评估其对腹膜内注射一剂10 μ mol NNK盐水溶液的A/J小鼠抑制肿瘤发展的有效性。此外,为了开始建立该机制,我们将使用肝微粒体进行其代谢,以确定p-XS-Asp是否将裂解成活性代谢物p-XSeH和阿司匹林,并评估已知受p-XSC和/或阿司匹林影响的考克斯-2介导的促有丝分裂MAPK和促存活PI 3 K/AKT信号通路。这些研究将开始确立p-XS-Asp作为肺癌预防剂的潜力。长期而言,p-XS- Asp作为一种有效且安全的药物的验证将降低发生肺癌的机会,特别是在吸烟者/前吸烟者中,从而直接降低死亡率。
公共卫生关系:到目前为止,还没有有效的药物可用于预防肺癌,其中约90%的病例归因于烟草使用。本文提出的研究将开始验证我们最近开发的杂合剂p-XS-Asp作为针对NNK诱导的致癌作用的有效且安全的化学预防剂,并开始阐明化学预防的潜在机制。如果有效,这项研究将揭示一种有前途的药物,在不久的将来,可以证明能够预防吸烟者的肺癌发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ARUN K SHARMA其他文献
ARUN K SHARMA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ARUN K SHARMA', 18)}}的其他基金
A novel compound for colorectal cancer prevention
一种预防结直肠癌的新型化合物
- 批准号:
8890808 - 财政年份:2014
- 资助金额:
$ 7.56万 - 项目类别:
A novel compound for colorectal cancer prevention
一种预防结直肠癌的新型化合物
- 批准号:
8786739 - 财政年份:2014
- 资助金额:
$ 7.56万 - 项目类别:
Development of a novel agent for lung cancer prevention
开发一种新型肺癌预防剂
- 批准号:
8507667 - 财政年份:2012
- 资助金额:
$ 7.56万 - 项目类别:
ISC-4 as a Novel Lung Cancer Chemopreventive Agent
ISC-4 作为新型肺癌化学预防剂
- 批准号:
7940968 - 财政年份:2009
- 资助金额:
$ 7.56万 - 项目类别:
ISC-4 as a Novel Lung Cancer Chemopreventive Agent
ISC-4 作为新型肺癌化学预防剂
- 批准号:
7792948 - 财政年份:2009
- 资助金额:
$ 7.56万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 7.56万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 7.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 7.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 7.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 7.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 7.56万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 7.56万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 7.56万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 7.56万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 7.56万 - 项目类别:
Discovery Grants Program - Individual